StockNews.com Downgrades Esperion Therapeutics (NASDAQ:ESPR) to Hold

StockNews.com downgraded shares of Esperion Therapeutics (NASDAQ:ESPR - Free Report) from a buy rating to a hold rating in a report released on Friday.

A number of other analysts have also recently weighed in on ESPR. Bank of America cut shares of Esperion Therapeutics from a neutral rating to an underperform rating and reduced their price objective for the stock from $2.90 to $2.50 in a research note on Thursday, June 20th. Needham & Company LLC cut their target price on Esperion Therapeutics from $8.00 to $6.00 and set a buy rating for the company in a research note on Tuesday, August 13th. Finally, HC Wainwright reissued a buy rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus target price of $8.17.

Esperion Therapeutics Price Performance

ESPR traded up $0.04 during trading on Friday, reaching $1.68. 946,099 shares of the stock were exchanged, compared to its average volume of 6,529,360. The business's 50 day moving average price is $1.91 and its two-hundred day moving average price is $2.21. The company has a market capitalization of $318.29 million, a price-to-earnings ratio of -1.68 and a beta of 1.00. Esperion Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.10. The firm had revenue of $73.83 million during the quarter, compared to the consensus estimate of $51.90 million. On average, analysts anticipate that Esperion Therapeutics will post -0.04 EPS for the current year.

Hedge Funds Weigh In On Esperion Therapeutics

Large investors have recently modified their holdings of the business. Jump Financial LLC bought a new stake in shares of Esperion Therapeutics during the fourth quarter valued at approximately $77,000. Armistice Capital LLC bought a new position in shares of Esperion Therapeutics in the fourth quarter worth approximately $9,568,000. Azimuth Capital Investment Management LLC purchased a new position in Esperion Therapeutics in the 4th quarter worth approximately $66,000. GSA Capital Partners LLP lifted its position in Esperion Therapeutics by 1.0% in the 4th quarter. GSA Capital Partners LLP now owns 1,128,149 shares of the biopharmaceutical company's stock valued at $3,373,000 after acquiring an additional 11,494 shares in the last quarter. Finally, Capital Advisors Wealth Management LLC bought a new stake in Esperion Therapeutics in the 1st quarter worth about $58,000. Hedge funds and other institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.